PL2076244T3 - Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie - Google Patents
Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanieInfo
- Publication number
- PL2076244T3 PL2076244T3 PL07873522T PL07873522T PL2076244T3 PL 2076244 T3 PL2076244 T3 PL 2076244T3 PL 07873522 T PL07873522 T PL 07873522T PL 07873522 T PL07873522 T PL 07873522T PL 2076244 T3 PL2076244 T3 PL 2076244T3
- Authority
- PL
- Poland
- Prior art keywords
- lipid
- compositions
- preparation
- methods
- aqueous systems
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85044606P | 2006-10-10 | 2006-10-10 | |
| US95702207P | 2007-08-21 | 2007-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2076244T3 true PL2076244T3 (pl) | 2017-05-31 |
Family
ID=39864519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07873522T PL2076244T3 (pl) | 2006-10-10 | 2007-10-10 | Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160310600A1 (pl) |
| EP (1) | EP2076244B1 (pl) |
| JP (2) | JP5917789B2 (pl) |
| CA (1) | CA2666322C (pl) |
| DK (1) | DK2076244T3 (pl) |
| ES (1) | ES2617747T3 (pl) |
| HU (1) | HUE031951T2 (pl) |
| PL (1) | PL2076244T3 (pl) |
| PT (1) | PT2076244T (pl) |
| WO (1) | WO2008127358A2 (pl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010510327A (ja) | 2006-11-21 | 2010-04-02 | ジャイナ ファーマシューティカルズ,インコーポレーテッド | エンドキシフェンの方法および組成物 |
| US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| PL2344198T3 (pl) * | 2008-09-27 | 2021-05-31 | Jina Pharmaceuticals Inc. | Preparaty farmaceutyczne na bazie lipidów do stosowania miejscowego |
| CA2765541A1 (en) | 2009-06-19 | 2010-12-23 | Sun Pharma Advanced Research Company Ltd. | Nanodispersion of a drug and process for its preparation |
| US8591942B2 (en) * | 2009-09-23 | 2013-11-26 | Indu JAVERI | Methods for the preparation of liposomes comprising docetaxel |
| US20170340563A1 (en) * | 2009-09-23 | 2017-11-30 | Curirx Inc. | Methods for the Preparation of Liposomes Comprising Drugs |
| MX341918B (es) | 2011-01-04 | 2016-09-07 | Archivel Farma Sl | Formulación de liposomas adecuada para tratar o prevenir la tuberculosis. |
| US9682042B2 (en) | 2012-01-12 | 2017-06-20 | Archivel Farma, S.L. | MTB-C vaccine against asthma |
| US10220095B2 (en) | 2013-03-15 | 2019-03-05 | Taiwan Liposome Company, Ltd | Controlled drug release liposome compositions and methods thereof |
| EP3060202A1 (en) * | 2013-10-21 | 2016-08-31 | Enzymotec Ltd. | Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation |
| ES3003920T3 (en) * | 2013-11-08 | 2025-03-11 | Activus Pharma Co Ltd | Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent |
| EP3150196A1 (en) * | 2015-09-30 | 2017-04-05 | Sun Pharma Advanced Research Company Ltd | Process for the preparation of unilamellar liposomal composition |
| AU2017205337B2 (en) * | 2016-01-07 | 2022-09-08 | Tesorx Pharma, Llc | Formulations for treating bladder cancer |
| PT3439668T (pt) * | 2016-04-08 | 2024-08-12 | Univ Illinois | Restauração da fisiologia da superfície das vias aéreas mediada por pequenas moléculas no epitélio pulmonar da fibrose quística humana |
| US20170290852A1 (en) * | 2016-04-08 | 2017-10-12 | Wisconsin Alumni Research Foundation | Micelle formulations of amphotericin b |
| AU2018225546A1 (en) * | 2017-02-21 | 2019-08-29 | Satellos Bioscience Inc. | Solid oral formulations of amphotericin B |
| WO2019055880A2 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | METHOD OF ADMINISTRATION AND TREATMENT |
| AU2018374593B2 (en) * | 2017-11-30 | 2021-09-09 | Shilpa Medicare Limited | Composition of docetaxel liposomal injection with high drug loading |
| EP3603682A1 (en) * | 2018-08-03 | 2020-02-05 | Alchilife S.r.l. | Tablet with an antimycotic agent, medical device and method for preserving harvested corneas |
| US11857680B2 (en) * | 2018-11-26 | 2024-01-02 | Shilpa Medicare Limited | Composition of docetaxel liposomal injection with high drug loading |
| CA3142510A1 (en) * | 2019-06-28 | 2020-12-30 | The Board Of Regents, The University Of Texas System | Preparation of preliposomal annamycin lyophilizate |
| CA3182909A1 (en) * | 2020-06-15 | 2021-12-23 | Aruna GORUSUPUDI | Retinal bioavailability of synthetic very-long-chain polyunsaturated fatty acids |
| US20230365619A1 (en) * | 2020-10-12 | 2023-11-16 | Durect Corporation | Crystalline sodium cholesteryl sulfate |
| WO2022081479A2 (en) * | 2020-10-12 | 2022-04-21 | Durect Corporation | Crystalline sodium cholesteryl sulfonate |
| CN119365218A (zh) | 2022-03-21 | 2025-01-24 | 伊利诺伊大学评议会 | 包含脂质包覆的两性霉素b晶体的离子通道假体组合物 |
| WO2025064631A1 (en) * | 2023-09-20 | 2025-03-27 | The Board Of Trustees Of The University Of Illinois | Use of a dry powder inhaler to treat or prevent pulmonary fungal infections |
| WO2025068971A1 (en) * | 2023-09-27 | 2025-04-03 | Jina Pharmaceuticals Inc. | Compositions containing cabazitaxel and lipids for oral administration |
| CN119326735A (zh) * | 2024-12-20 | 2025-01-21 | 哈尔滨医科大学 | 一种秋水仙碱制剂及其在制备治疗器官纤维化疾病药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5782311A (en) * | 1980-11-11 | 1982-05-22 | Tanabe Seiyaku Co Ltd | Production of liposome preparation |
| JPS5782310A (en) * | 1980-11-11 | 1982-05-22 | Tanabe Seiyaku Co Ltd | Production of liposome preparation |
| JPS6058915A (ja) * | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
| US5084269A (en) * | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
| MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| WO1992007552A1 (fr) * | 1990-11-06 | 1992-05-14 | Nippon Shinyaku Co., Ltd. | Preparation lyophilisee et sa production |
| DE4207481A1 (de) * | 1992-03-10 | 1993-09-16 | Bayer Ag | Liposomale wirkstoff-formulierungen und verfahren zu ihrer herstellung |
| ATE223205T1 (de) * | 1994-11-18 | 2002-09-15 | Aphios Corp | Verfahren zur herstellung von liposomen, die hydrophobische artzneistoffe enthalten |
| MXPA03003401A (es) * | 2000-10-16 | 2004-06-30 | Neopharm Inc | Formulacion liposomica de mitoxantrona. |
| CZ20031515A3 (cs) * | 2000-11-09 | 2003-09-17 | Neopharm, Inc. | Komplexy SN-38 s lipidem a způsob jejich použití |
| EP1531800B1 (en) * | 2002-06-11 | 2011-06-08 | Ethypharm | Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| WO2005044229A1 (en) * | 2003-11-05 | 2005-05-19 | The Australian National University | Dispersions and methods of preparing them |
| EP1809254A2 (en) * | 2004-10-28 | 2007-07-25 | Alza Corporation | Lyophilized liposome formulations and method |
-
2007
- 2007-10-10 CA CA2666322A patent/CA2666322C/en active Active
- 2007-10-10 EP EP07873522.2A patent/EP2076244B1/en active Active
- 2007-10-10 WO PCT/US2007/080984 patent/WO2008127358A2/en not_active Ceased
- 2007-10-10 DK DK07873522.2T patent/DK2076244T3/en active
- 2007-10-10 PT PT78735222T patent/PT2076244T/pt unknown
- 2007-10-10 PL PL07873522T patent/PL2076244T3/pl unknown
- 2007-10-10 ES ES07873522.2T patent/ES2617747T3/es active Active
- 2007-10-10 HU HUE07873522A patent/HUE031951T2/en unknown
- 2007-10-10 JP JP2009532562A patent/JP5917789B2/ja active Active
-
2015
- 2015-10-02 JP JP2015196744A patent/JP2016041704A/ja active Pending
-
2016
- 2016-07-07 US US15/204,826 patent/US20160310600A1/en not_active Abandoned
-
2020
- 2020-07-09 US US16/924,529 patent/US20200345849A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010505965A (ja) | 2010-02-25 |
| HUE031951T2 (en) | 2017-08-28 |
| EP2076244A2 (en) | 2009-07-08 |
| US20160310600A1 (en) | 2016-10-27 |
| PT2076244T (pt) | 2017-03-09 |
| DK2076244T3 (en) | 2017-02-27 |
| US20200345849A1 (en) | 2020-11-05 |
| EP2076244A4 (en) | 2013-01-09 |
| EP2076244B1 (en) | 2016-12-07 |
| WO2008127358A2 (en) | 2008-10-23 |
| CA2666322A1 (en) | 2008-10-23 |
| WO2008127358A3 (en) | 2008-12-24 |
| CA2666322C (en) | 2013-04-23 |
| JP2016041704A (ja) | 2016-03-31 |
| JP5917789B2 (ja) | 2016-05-18 |
| ES2617747T3 (es) | 2017-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2076244T (pt) | Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos | |
| AU2007299727A8 (en) | Self preserved aqueous pharmaceutical compositions | |
| IL193772A0 (en) | 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same | |
| IL195488A (en) | Compounds, pharmaceuticals containing them and their uses | |
| ZA200900347B (en) | Preparation of pharmaceutical compositions | |
| IL196280A0 (en) | Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them | |
| IL198289A (en) | Processed dihydropyrazolones, processes for their preparation, medicinal preparations containing them and their use in the preparation of medicinal preparations | |
| ZA200901702B (en) | Self-preserved aqueous pharmaceutical compositions | |
| EP1841761A4 (en) | Fumagillol derivatives or processes for the preparation of fumagillol derivatives, and pharmaceutical compositions containing them | |
| ZA200903533B (en) | Process for the preparation of rosuvastatin | |
| IL195528A (en) | Pyridazine compound, methods of preparation, a pharmaceutical composition containing it, its use and intermediate material | |
| IL197877A (en) | Uses of aminomethyl-4-imidazole derivatives for the preparation of medications and medications containing them | |
| IL194961A0 (en) | Compounds a-r-x for the manufacture of pharmaceutical preparations | |
| IL213452A0 (en) | Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | |
| PT2210872T (pt) | Nova forma cristalina iii de agomelatina, processo para a sua preparação e composições farmacêuticas que a contêm | |
| ZA201007610B (en) | Processes for the preparation of benzo-fused dioxin derivatives | |
| PT2193795E (pt) | Composição farmacêutica aquosa contendo latanoprost | |
| WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
| PL2231598T3 (pl) | Nowe pochodne diazeniodiolanów, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające | |
| WO2008081268A3 (en) | Pharmaceutical compositions of entacapone | |
| IL213474A0 (en) | Processes for the preparation of cyclopropyl-amide derivatives | |
| ZA200901164B (en) | Self preserved aqueous pharmaceutical compositions | |
| HUP0600293A2 (en) | Zinc salt of rosuvastatine, process for its preparation and pharmaceutical compositions containing it | |
| IL214028A (en) | A cyanopyrimidine or salt compound, a pharmaceutical preparation containing it, its use and an aqueous liquid containing the said pharmaceutical composition | |
| ZA200806399B (en) | Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them |